The minimum total value of these contracts is $1.6 million, the majority of which will be recognized in the current fiscal year. These orders bring the minimum total value of the pharmaceutical trial contracts secured by AtCor over the past 60 days to over $2.8 million.
Duncan Ross, CEO of AtCor Medical, said: “The growing use of SphygmoCor systems in clinical trials and increasing volume of publication concerning central blood pressures and arterial stiffness indicate a move toward establishing a new standard for cardiovascular risk assessment and management.”